The Filing Desk

Foghorn Therapeutics vs Scilex

Foghorn Therapeutics FHTX · Scilex SCLX · Pharmaceuticals

Foghorn Therapeutics reported revenue of $31 million in fiscal 2025, about the same as Scilex's $30 million in fiscal 2025. Foghorn Therapeutics' revenue grew 36.8% in its latest year, and Scilex's fell 46.5%. Foghorn Therapeutics had an operating margin of -279.5%, against -1143.7% at Scilex. Free cash flow was −$86 million at Foghorn Therapeutics and $4 million at Scilex.

Side by side

Foghorn TherapeuticsScilex
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$31M$30M
Revenue growth36.8%−46.5%
Revenue growth a year, last 5 years138.6%5.1%
Gross margin——
Operating margin−279.5%−1,143.7%
Net margin−240.3%−1,236.4%
Free cash flow−$86M$4M
Free cash flow margin−278.7%12.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count14.7%108,662.9%
Last close$1.78$0.65
P/E at the last close25.4×—
Insider trades, last 12 months—sold $12.8 million
Piotroski F-score2 of 83 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Foghorn TherapeuticsScilex
Operating margin
Percent of revenue
Foghorn TherapeuticsScilex
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Foghorn TherapeuticsScilex

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Foghorn Therapeutics and Scilex pages.